Wuze Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-12-2024
- Paid Up Capital ₹ 0.10 M
as on 24-12-2024
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -60.89%
(FY 2023)
- Profit -190.64%
(FY 2023)
- Ebitda -10.01%
(FY 2023)
- Net Worth -16.11%
(FY 2023)
- Total Assets 5.39%
(FY 2023)
About Wuze Pharmaceuticals
The Company is engaged in the E-Commerce Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Praveen Singla and Mansi Aggarwal serve as directors at the Company.
- CIN/LLPIN
U74999DL2018PTC328905
- Company No.
328905
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jan 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Wuze Pharmaceuticals Private Limited offer?
Wuze Pharmaceuticals Private Limited offers a wide range of products and services, including Juices, Soups & Soft Drinks, Fruit Juice, Ayurvedic & Herbal Health Supplement, Herbal Juice, Herbal Extracts, Green Tea Extract, Herbal Foods Beverages, Green Tea Capsules, Non Alcohol Drinks, Sea Buckthorn Juice.
Who are the key members and board of directors at Wuze Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Praveen Singla  | Director | 24-Jan-2018 | Current |
| Mansi Aggarwal | Director | 01-Aug-2022 | Current |
Financial Performance of Wuze Pharmaceuticals.
Wuze Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 60.89% decrease. The company also saw a substantial fall in profitability, with a 190.64% decrease in profit. The company's net worth observed a substantial decline by a decrease of 16.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wuze Pharmaceuticals?
In 2023, Wuze Pharmaceuticals had a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wuze Pharmaceuticals?
Unlock and access historical data on people associated with Wuze Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wuze Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wuze Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
